

H#



ENTERED

PCT09

RAW SEQUENCE LISTING

DATE: 02/06/2003

PATENT APPLICATION: US/09/720,933A

TIME: 15:14:06

Input Set : A:\002201.txt

Output Set: N:\CRF4\02052003\I720933A.raw

```

3 <110> APPLICANT: BURGER, Elisabeth Henriette
4     VAN NIEUW AMERONGEN, Arie
5     WUISMAN, Paulus Ignatius Jozef
7 <120> TITLE OF INVENTION: Bone Cement With Antimicrobial Peptides
9 <130> FILE REFERENCE: 702 002201
11 <140> CURRENT APPLICATION NUMBER: 09/720,933A
12 <141> CURRENT FILING DATE: 1999-07-02
14 <150> PRIOR APPLICATION NUMBER: EP 98202233.7
15 <151> PRIOR FILING DATE: 1998-07-02
17 <160> NUMBER OF SEQ ID NOS: 16
19 <170> SOFTWARE: MS Word 97 SR-2
21 <210> SEQ ID NO: 1
22 <211> LENGTH: 14
23 <212> TYPE: PRT
24 <213> ORGANISM: Artificial Sequence
26 <220> FEATURE:
27 <223> OTHER INFORMATION: Obtained by direct synthesis.
28     Peptide is hydrophobic on one side and hydrophilic on the other.
30 <400> SEQUENCE: 1
31 Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr
32   1             5             10
34 <210> SEQ ID NO: 2
35 <211> LENGTH: 14
36 <212> TYPE: PRT
37 <213> ORGANISM: Artificial Sequence
39 <220> FEATURE:
40 <223> OTHER INFORMATION: Obtained by direct synthesis.
41     Peptide is hydrophobic on one side and hydrophilic on the other.
43 <400> SEQUENCE: 2
44 Lys Arg Leu Phe Lys Glu Leu Leu Phe Ser Leu Arg Lys Tyr
45   1             5             10
47 <210> SEQ ID NO: 3
48 <211> LENGTH: 14
49 <212> TYPE: PRT
50 <213> ORGANISM: Artificial Sequence
52 <220> FEATURE:
53 <223> OTHER INFORMATION: Obtained by direct synthesis.
54     Peptide is hydrophobic on one side and hydrophilic on the other.
56 <400> SEQUENCE: 3
57 Lys Arg Leu Phe Lys Glu Leu Lys Lys Ser Leu Arg Lys Tyr
58   1             5             10
60 <210> SEQ ID NO: 4
61 <211> LENGTH: 14

```

RAW SEQUENCE LISTING

DATE: 02/06/2003

PATENT APPLICATION: US/09/720,933A

TIME: 15:14:06

Input Set : A:\002201.txt

Output Set: N:\CRF4\02052003\I720933A.raw

```

62 <212> TYPE: PRT
63 <213> ORGANISM: Artificial Sequence
65 <220> FEATURE:
66 <223> OTHER INFORMATION: Obtained by direct synthesis.
67     Peptide is hydrophobic on one side and hydrophilic on the other.
69 <400> SEQUENCE: 4
70 Lys Arg Leu Phe Lys Glu Leu Leu Lys Ser Leu Arg Lys Tyr
71   1             5             10
73 <210> SEQ ID NO: 5
74 <211> LENGTH: 14
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Obtained by direct synthesis.
80     Peptide is hydrophobic on one side and hydrophilic on the other.
82 <220> FEATURE:
83 <221> NAME/KEY: SITE
84 <222> LOCATION: 1
85 <223> OTHER INFORMATION: Orn
87 <220> FEATURE:
88 <221> NAME/KEY: SITE
89 <222> LOCATION: 2
90 <223> OTHER INFORMATION: Orn
92 <220> FEATURE:
93 <221> NAME/KEY: SITE
94 <222> LOCATION: 5
95 <223> OTHER INFORMATION: Orn
97 <220> FEATURE:
98 <221> NAME/KEY: SITE
99 <222> LOCATION: 8
100 <223> OTHER INFORMATION: Orn
102 <220> FEATURE:
103 <221> NAME/KEY: SITE
104 <222> LOCATION: 9
105 <223> OTHER INFORMATION: Orn
107 <220> FEATURE:
108 <221> NAME/KEY: SITE
109 <222> LOCATION: 12
110 <223> OTHER INFORMATION: Orn
112 <220> FEATURE:
113 <221> NAME/KEY: SITE
114 <222> LOCATION: 13
115 <223> OTHER INFORMATION: Orn
117 <400> SEQUENCE: 5
W--> 118 Xaa Xaa Leu Phe Xaa Glu Leu Xaa Xaa Ser Leu Xaa Xaa Tyr
119   1             5             10
121 <210> SEQ ID NO: 6
122 <211> LENGTH: 14
123 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 02/06/2003

PATENT APPLICATION: **US/09/720,933A**

TIME: 15:14:06

Input Set : **A:\002201.txt**Output Set: **N:\CRF4\02052003\I720933A.raw**

```

124 <213> ORGANISM: Artificial Sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: Obtained by direct synthesis.
128     Peptide is hydrophobic on one side and hydrophilic on the other.
130 <220> FEATURE:
131 <221> NAME/KEY: SITE
132 <222> LOCATION: 1
133 <223> OTHER INFORMATION: Orn
135 <220> FEATURE:
136 <221> NAME/KEY: SITE
137 <222> LOCATION: 2
138 <223> OTHER INFORMATION: Orn
140 <220> FEATURE:
141 <221> NAME/KEY: SITE
142 <222> LOCATION: 5
143 <223> OTHER INFORMATION: Orn
145 <220> FEATURE:
146 <221> NAME/KEY: SITE
147 <222> LOCATION: 9
148 <223> OTHER INFORMATION: Orn
150 <220> FEATURE:
151 <221> NAME/KEY: SITE
152 <222> LOCATION: 12
153 <223> OTHER INFORMATION: Orn
155 <220> FEATURE:
156 <221> NAME/KEY: SITE
157 <222> LOCATION: 13
158 <223> OTHER INFORMATION: Orn
160 <400> SEQUENCE: 6
W--> 161 Xaa Xaa Leu Phe Xaa Glu Leu Leu Xaa Ser Leu Xaa Xaa Tyr
162     1             5             10
164 <210> SEQ ID NO: 7
165 <211> LENGTH: 14
166 <212> TYPE: PRT
167 <213> ORGANISM: Artificial Sequence
169 <220> FEATURE:
170 <223> OTHER INFORMATION: Obtained by direct synthesis.
171     Peptide is hydrophobic on one side and hydrophilic on the other.
173 <400> SEQUENCE: 7
174 Lys Arg Leu Phe Lys Lys Leu Lys Phe Ser Leu Arg Lys Tyr
175     1             5             10
177 <210> SEQ ID NO: 8
178 <211> LENGTH: 14
179 <212> TYPE: PRT
180 <213> ORGANISM: Artificial Sequence
182 <220> FEATURE:
183 <223> OTHER INFORMATION: Obtained by direct synthesis.
184     Peptide is hydrophobic on one side and hydrophilic on the other.
186 <400> SEQUENCE: 8

```

RAW SEQUENCE LISTING

DATE: 02/06/2003

PATENT APPLICATION: US/09/720,933A

TIME: 15:14:06

Input Set : A:\002201.txt

Output Set: N:\CRF4\02052003\I720933A.raw

```

187 Lys Arg Leu Phe Lys Lys Leu Leu Phe Ser Leu Arg Lys Tyr
188   1               5               10
190 <210> SEQ ID NO: 9
191 <211> LENGTH: 14
192 <212> TYPE: PRT
193 <213> ORGANISM: Artificial Sequence
195 <220> FEATURE:
196 <223> OTHER INFORMATION: Obtained by direct synthesis.
197     Peptide is hydrophobic at one end and hydrophobic at the other.
199 <400> SEQUENCE: 9
200 Leu Leu Leu Phe Leu Leu Lys Lys Arg Lys Lys Arg Lys Tyr
201   1               5               10
203 <210> SEQ ID NO: 10
204 <211> LENGTH: 14
205 <212> TYPE: PRT
206 <213> ORGANISM: Artificial Sequence
208 <220> FEATURE:
209 <223> OTHER INFORMATION: Obtained by direct synthesis, with replacement of the
210     C-terminal carboxylic acid group.
212 <220> FEATURE:
213 <221> NAME/KEY: AMIDATION
214 <222> LOCATION: 14
215 <223> OTHER INFORMATION: C-Terminus is modified.
217 <400> SEQUENCE: 10
218 Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr
219   1               5               10
221 <210> SEQ ID NO: 11
222 <211> LENGTH: 14
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: Obtained by direct synthesis, with replacement of the
228     C-terminal carboxylic acid group.
230 <220> FEATURE:
231 <221> NAME/KEY: AMIDATION
232 <222> LOCATION: 14
233 <223> OTHER INFORMATION: C-Terminus is modified.
235 <400> SEQUENCE: 11
236 Lys Arg Leu Phe Lys Glu Leu Leu Phe Ser Leu Arg Lys Tyr
237   1               5               10
239 <210> SEQ ID NO: 12
240 <211> LENGTH: 30
241 <212> TYPE: PRT
242 <213> ORGANISM: Artificial Sequence
244 <220> FEATURE:
245 <223> OTHER INFORMATION: Oligomer
246     Obtained by direct synthesis, followed by conversion to
247     oligomer by air oxidation.
249 <400> SEQUENCE: 12

```

RAW SEQUENCE LISTING

DATE: 02/06/2003

PATENT APPLICATION: US/09/720,933A

TIME: 15:14:06

Input Set : A:\002201.txt

Output Set: N:\CRF4\02052003\I720933A.raw

```

250 Lys Arg Lys Phe His Glu Lys His His Ser His Arg Gly Tyr Cys Cys
251   1           5           10           15
252 Tyr Gly Arg His Ser His His Lys Glu His Phe Lys Arg Lys
253           20           25           30
255 <210> SEQ ID NO: 13
256 <211> LENGTH: 30
257 <212> TYPE: PRT
258 <213> ORGANISM: Artificial Sequence
260 <220> FEATURE:
261 <223> OTHER INFORMATION: Oligomer
262     Obtained by direct synthesis, followed by conversion to
263     oligomer by air oxidation.
265 <400> SEQUENCE: 13
266 Tyr Gly Arg His Ser His His Lys Glu His Phe Lys Arg Lys Cys Cys
267   1           5           10           15
268 Lys Arg Lys Phe His Glu Lys His His Ser His Arg Gly Tyr
269           20           25           30
271 <210> SEQ ID NO: 14
272 <211> LENGTH: 14
273 <212> TYPE: PRT
274 <213> ORGANISM: Artificial Sequence
276 <220> FEATURE:
277 <223> OTHER INFORMATION: Obtained by direct synthesis followed by the use of the
278     Multiple Antigenic Peptide (MAP) strategy.
280 <220> FEATURE:
281 <221> NAME/KEY: MOD_RES
282 <222> LOCATION: 14
283 <223> OTHER INFORMATION: Peptides linked by lysine-amide to form oligomer.
285 <400> SEQUENCE: 14
286 Lys Arg Lys Phe His Glu Lys His His Ser His Arg Gly Tyr
287   1           5           10
289 <210> SEQ ID NO: 15
290 <211> LENGTH: 14
291 <212> TYPE: PRT
292 <213> ORGANISM: Artificial Sequence
294 <220> FEATURE:
295 <223> OTHER INFORMATION: Obtained by direct synthesis followed by the use of the
296     Multiple Antigenic Peptide (MAP) strategy.
298 <220> FEATURE:
299 <221> NAME/KEY: MOD_RES
300 <222> LOCATION: 14
301 <223> OTHER INFORMATION: Peptides linked by lysine-amide to form oligomer.
303 <400> SEQUENCE: 15
304 Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr
305   1           5           10
307 <210> SEQ ID NO: 16
308 <211> LENGTH: 14
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 02/06/2003
PATENT APPLICATION: US/09/720,933A TIME: 15:14:07

Input Set : A:\002201.txt
Output Set: N:\CRF4\02052003\I720933A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:5; Xaa Pos. 1,2,5,8,9,12,13

Seq#:6; Xaa Pos. 1,2,5,9,12,13

VERIFICATION SUMMARYPATENT APPLICATION: **US/09/720,933A**

DATE: 02/06/2003

TIME: 15:14:07

Input Set : **A:\002201.txt**Output Set: **N:\CRF4\02052003\I720933A.raw**

L:118 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
L:161 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0